Ongoing research aims to better understand the molecular mechanisms governing CHK1 activation and function, as well as its interactions with other DNA damage response pathways. Additionally, there is a focus on identifying biomarkers that can predict response to CHK1 inhibitors, improving patient selection for these therapies. Combining CHK1 inhibitors with other targeted therapies and immunotherapies is also an area of active investigation, with the goal of enhancing anti-tumor efficacy and overcoming resistance.
In summary, the CHK1 pathway is a crucial element in the cellular response to DNA damage and replication stress, playing a significant role in cancer cell survival. Targeting CHK1 offers a promising therapeutic strategy, particularly when combined with other treatments. However, challenges such as resistance and toxicity must be addressed to fully realize the potential of CHK1 inhibitors in cancer therapy.
